These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

565 related articles for article (PubMed ID: 15752837)

  • 1. Production of yellow fever 17DD vaccine virus in primary culture of chicken embryo fibroblasts: yields, thermo and genetic stability, attenuation and immunogenicity.
    Freire MS; Mann GF; Marchevsky RS; Yamamura AM; Almeida LF; Jabor AV; Malachias JM; Coutinho ES; Galler R
    Vaccine; 2005 Mar; 23(19):2501-12. PubMed ID: 15752837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular and phenotypic analysis of a working seed lot of yellow fever virus 17DD vaccine strain produced from the secondary seed lot 102/84 with an additional passage in chicken embryos.
    Marchevsky RS; da Luz Leal M; Homma A; Coutinho ES; Camacho LA; Jabor AV; Galler R; Freire MS
    Biologicals; 2006 Sep; 34(3):191-7. PubMed ID: 16326110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence for interferon production and its correlation with YF 17DD vaccine virus yields in primary chick embryo cells.
    Caride E; Borges MB; Marcovistz R; Galler R; Freire Mda S
    Virus Res; 2008 Oct; 137(1):106-11. PubMed ID: 18621087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Construction and biological properties of yellow fever 17D/dengue type 1 recombinant virus.
    Mateu GP; Marchevsky RS; Liprandi F; Bonaldo MC; Coutinho ES; Dieudonné M; Caride E; Jabor AV; Freire MS; Galler R
    Trans R Soc Trop Med Hyg; 2007 Mar; 101(3):289-98. PubMed ID: 17169387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pressure-inactivated yellow fever 17DD virus: implications for vaccine development.
    Gaspar LP; Mendes YS; Yamamura AM; Almeida LF; Caride E; Gonçalves RB; Silva JL; Oliveira AC; Galler R; Freire MS
    J Virol Methods; 2008 Jun; 150(1-2):57-62. PubMed ID: 18420285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates.
    Guirakhoo F; Pugachev K; Arroyo J; Miller C; Zhang ZX; Weltzin R; Georgakopoulos K; Catalan J; Ocran S; Draper K; Monath TP
    Virology; 2002 Jun; 298(1):146-59. PubMed ID: 12093182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis.
    Guirakhoo F; Zhang ZX; Chambers TJ; Delagrave S; Arroyo J; Barrett AD; Monath TP
    Virology; 1999 May; 257(2):363-72. PubMed ID: 10329547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High stability of yellow fever 17D-204 vaccine: a 12-year restrospective analysis of large-scale production.
    Barban V; Girerd Y; Aguirre M; Gulia S; Pétiard F; Riou P; Barrere B; Lang J
    Vaccine; 2007 Apr; 25(15):2941-50. PubMed ID: 16914238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurovirulence of yellow fever 17DD vaccine virus to rhesus monkeys.
    Marchevsky RS; Freire MS; Coutinho ES; Galler R
    Virology; 2003 Nov; 316(1):55-63. PubMed ID: 14599790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A single amino acid substitution in the envelope protein of chimeric yellow fever-dengue 1 vaccine virus reduces neurovirulence for suckling mice and viremia/viscerotropism for monkeys.
    Guirakhoo F; Zhang Z; Myers G; Johnson BW; Pugachev K; Nichols R; Brown N; Levenbook I; Draper K; Cyrek S; Lang J; Fournier C; Barrere B; Delagrave S; Monath TP
    J Virol; 2004 Sep; 78(18):9998-10008. PubMed ID: 15331733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized, double-blind, multicenter study of the immunogenicity and reactogenicity of 17DD and WHO 17D-213/77 yellow fever vaccines in children: implications for the Brazilian National Immunization Program.
    Collaborative Group for Studies with Yellow Fever Vaccine
    Vaccine; 2007 Apr; 25(16):3118-23. PubMed ID: 17316925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Attenuation of recombinant yellow fever 17D viruses expressing foreign protein epitopes at the surface.
    Bonaldo MC; Garratt RC; Marchevsky RS; Coutinho ES; Jabor AV; Almeida LF; Yamamura AM; Duarte AS; Oliveira PJ; Lizeu JO; Camacho LA; Freire MS; Galler R
    J Virol; 2005 Jul; 79(13):8602-13. PubMed ID: 15956601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phenotypic and molecular analyses of yellow fever 17DD vaccine viruses associated with serious adverse events in Brazil.
    Galler R; Pugachev KV; Santos CL; Ocran SW; Jabor AV; Rodrigues SG; Marchevsky RS; Freire MS; Almeida LF; Cruz AC; Yamamura AM; Rocco IM; da Rosa ES; Souza LT; Vasconcelos PF; Guirakhoo F; Monath TP
    Virology; 2001 Nov; 290(2):309-19. PubMed ID: 11883195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phenotypic analysis of yellow fever virus derived from complementary DNA.
    Marchevsky RS; Mariano J; Ferreira VS; Almeida E; Cerqueira MJ; Carvalho R; Pissurno JW; da Rosa AP; Simoes MC; Santos CN
    Am J Trop Med Hyg; 1995 Jan; 52(1):75-80. PubMed ID: 7856829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutation in a 17D-204 vaccine substrain-specific envelope protein epitope alters the pathogenesis of yellow fever virus in mice.
    Ryman KD; Ledger TN; Campbell GA; Watowich SJ; Barrett AD
    Virology; 1998 Apr; 244(1):59-65. PubMed ID: 9581778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates.
    Monath TP; Soike K; Levenbook I; Zhang ZX; Arroyo J; Delagrave S; Myers G; Barrett AD; Shope RE; Ratterree M; Chambers TJ; Guirakhoo F
    Vaccine; 1999 Apr; 17(15-16):1869-82. PubMed ID: 10217584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inactivated yellow fever 17D vaccine: development and nonclinical safety, immunogenicity and protective activity.
    Monath TP; Lee CK; Julander JG; Brown A; Beasley DW; Watts DM; Hayman E; Guertin P; Makowiecki J; Crowell J; Levesque P; Bowick GC; Morin M; Fowler E; Trent DW
    Vaccine; 2010 May; 28(22):3827-40. PubMed ID: 20347059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An inactivated yellow fever 17DD vaccine cultivated in Vero cell cultures.
    Pereira RC; Silva AN; Souza MC; Silva MV; Neves PP; Silva AA; Matos DD; Herrera MA; Yamamura AM; Freire MS; Gaspar LP; Caride E
    Vaccine; 2015 Aug; 33(35):4261-8. PubMed ID: 25862300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sanger-based sequencing technology for yellow fever vaccine genetic quality control.
    Pestana CP; Lawson-Ferreira R; Lessa-Aquino C; Leal MDLF; Freire MDS; Homma A; Medeiros MA
    J Virol Methods; 2018 Oct; 260():82-87. PubMed ID: 30009851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The use of tapioca as coverage in viral titration].
    Post PR; de Carvalho R; Brito EC; Galler R
    An Acad Bras Cienc; 1992; 64(1):79-86. PubMed ID: 1492720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.